Literature DB >> 20189027

Dilated cardiomyopathy.

John Lynn Jefferies1, Jeffrey A Towbin.   

Abstract

Dilated cardiomyopathy is characterised by left ventricular dilation that is associated with systolic dysfunction. Diastolic dysfunction and impaired right ventricular function can develop. Affected individuals are at risk of left or right ventricular failure, or both. Heart failure symptoms can be exercise-induced or persistent at rest. Many patients are asymptomatic. Chronically treated patients sometimes present acutely with decompensated heart failure. Other life-threatening risks are ventricular arrhythmias and atrioventricular block, syncope, and sudden death. Genetic inheritance arises in 30-48% of patients, and inflammatory disorders such as myocarditis or toxic effects from medications, alcohol, or illicit drugs also result in dilated cardiomyopathy. Genes that cause dilated cardiomyopathy generally encode cytoskeletal and sarcomeric (contractile apparatus) proteins, although disturbance of calcium homeostasis also seems to be important. In children, disrupted mitochondrial function and metabolic abnormalities have a causal role. Treatments focus on improvement of cardiac efficiency and reduction of mechanical stress. Arrhythmia therapy and prevention of sudden death continue to be mainstays of treatment. Despite progress over the past 10 years, outcomes need to be improved. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20189027     DOI: 10.1016/S0140-6736(09)62023-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  177 in total

1.  Role of genomics in cardiovascular medicine.

Authors:  Giuseppe Novelli; Irene M Predazzi; Ruggiero Mango; Francesco Romeo; Jawahar L Mehta
Journal:  World J Cardiol       Date:  2010-12-26

2.  Cardiovascular magnetic resonance tagging imaging correlates with myocardial dysfunction and T2 mapping in idiopathic dilated cardiomyopathy.

Authors:  Atsushi K Kono; Pierre Croisille; Tatsuya Nishii; Koya Nishiyama; Katsusuke Kyotani; Mayumi Shigeru; Sachiko Takamine; Sei Fujiwara; Kazuro Sugimura
Journal:  Int J Cardiovasc Imaging       Date:  2014-08-26       Impact factor: 2.357

3.  Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations.

Authors:  Enkhsaikhan Purevjav; Takuro Arimura; Sibylle Augustin; Anne-Cecile Huby; Ken Takagi; Shinichi Nunoda; Debra L Kearney; Michael D Taylor; Fumio Terasaki; Johan M Bos; Steve R Ommen; Hiroki Shibata; Megumi Takahashi; Manatsu Itoh-Satoh; William J McKenna; Ross T Murphy; Siegfried Labeit; Yoichi Yamanaka; Noboru Machida; Jeong-Euy Park; Peta M A Alexander; Robert G Weintraub; Yasushi Kitaura; Michael J Ackerman; Akinori Kimura; Jeffrey A Towbin
Journal:  Hum Mol Genet       Date:  2012-01-27       Impact factor: 6.150

Review 4.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy.

Authors:  Ray E Hershberger; Jill D Siegfried
Journal:  J Am Coll Cardiol       Date:  2011-04-19       Impact factor: 24.094

Review 5.  Genetics of inherited cardiomyopathy.

Authors:  Daniel Jacoby; William J McKenna
Journal:  Eur Heart J       Date:  2011-08-02       Impact factor: 29.983

6.  Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A.

Authors:  Kim N Ha; Larry R Masterson; Zhanjia Hou; Raffaello Verardi; Naomi Walsh; Gianluigi Veglia; Seth L Robia
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

7.  Increased myocardial native T1 relaxation time in patients with nonischemic dilated cardiomyopathy with complex ventricular arrhythmia.

Authors:  Shiro Nakamori; An H Bui; Jihye Jang; Hossam A El-Rewaidy; Shingo Kato; Long H Ngo; Mark E Josephson; Warren J Manning; Reza Nezafat
Journal:  J Magn Reson Imaging       Date:  2017-07-24       Impact factor: 4.813

8.  Acute inotropic and lusitropic effects of cardiomyopathic R9C mutation of phospholamban.

Authors:  Neha Abrol; Pieter P de Tombe; Seth L Robia
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

9.  Cardiac Rehabilitation Improves Cardiometabolic Health in Young Patients with Nonischemic Dilated Cardiomyopathy.

Authors:  Samuel G Wittekind; Yvette Gerdes; Wayne Mays; Clifford Chin; John L Jefferies
Journal:  Tex Heart Inst J       Date:  2018-02-01

10.  Association of genetic polymorphisms on BTNL2 with susceptibility to and prognosis of dilated cardiomyopathy in a Chinese population.

Authors:  Liang Cheng; Rong Zhao; ZhenXiao Jin; Kai Ren; Chao Deng; Shiqiang Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.